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Abstract
Background: Serum phosphatidylethanol (PEth) is a highly sensitive test to detect alco-
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hol use. We evaluated whether the availability of PEth testing impacted rates of liver
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transplant evaluation terminations and delistings.
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Methods: Medical record data were collected for patients who initiated transplant
evaluation due to alcohol-related liver disease in the pre-PEth (2017) or PEth (2019)
eras. Inverse probability weighting (IPW) was used to balance baseline patient characteristics. Outcomes included termination of evaluation or delisting due to alcohol
use; patients were censored at receipt of transplant; death was considered a competing
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risk. The Fine-Gray method was performed to determine whether PEth testing affected
risk of evaluation termination/ delisting due to alcohol use.
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Results: Three hundred and seventy-five patients with alcohol-related indications for
transplant (157 in 2017; 210 in 2019) were included. The final IPW-adjusted model for
the composite outcome of terminations/delisting due to alcohol use retained two significant variables (P < .05): PEth era and BMI category. Patients evaluated during the
PEth era were almost three times more likely to experience an alcohol-related termination/delisting than those in the pre-PEth era (sHR = 2.86; 95%CI 1.67–4.97)
Conclusion: We found that availability of PEth testing at our institution was associated with a higher rate of exclusion of patients from eligibility for liver transplant. Use
of PEth testing has significant potential to inform decisions regarding transplant candidacy for patients with alcohol-related liver disease.
KEYWORDS

alcoholic liver disease, delisting, evaluation termination, liver transplantation, PEth, phosphatidyl
ethanol, waitlist outcomes
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INTRODUCTION

excluded. Within our health system, all transplant candidates with
alcohol-related liver disease are evaluated by a transplant psycholo-

Alcohol (ethanol) is one of the most common causes of chronic liver

gist. Patients receive individual counseling about the necessity of per-

disease.1 Alcohol-related liver disease causes roughly half of all cir-

manent discontinuation of alcohol use and are required to enroll in an

rhosis worldwide; a recent report noted that alcohol-related cirrho-

alcohol relapse prevention program. They are informed that they will

sis was responsible for 21% of orthotopic liver transplants in the

be tested for alcohol use at the beginning of the evaluation and may be

States.2,3

In the past, many liver transplant programs in the

tested intermittently prior to transplant; testing may be random, due

United States required patients with alcohol-related cirrhosis to ful-

to clinical deterioration, or suspicion of resumed alcohol use. In 2017,

fill a “six-month rule” of abstinence from alcohol.3 More recently,

blood or urine alcohol testing was used; after PEth testing was intro-

however, many transplant programs have adopted policies of evaluat-

duced, other methods of testing were discontinued. Finally, patients

ing transplant candidates on a “case-by-case” basis, allowing patients

sign a contract confirming they understand our institution’s policies.

with alcohol-related hepatitis and recent alcohol use to be considered

At the time of this analysis (2017–2019), HFHS had a “zero tolerance”

for transplant.4 This has expanded the pool of patients with alcohol-

policy for use of alcohol during the evaluation period and while on the

related liver disease being considered for transplant. Accurate assess-

transplant waitlist; a positive test for alcohol use resulted in termina-

ment of alcohol use has therefore become imperative.

tion of the transplant evaluation or removal from the waitlist, without

United

Studies have shown that serum measures of phosphatidylethanol

future opportunities to be considered for transplant at our institution.

(PEth)—a group of phospholipids formed only in the presence of

The option for status 7/temporary inactive list was not used for a posi-

ethanol via the action of phospholipase D—can identify recent alco-

tive alcohol result; all evaluation terminations/delistings due to alcohol

hol use with high sensitivity and specificity; with a half-life of 4.5–

use were final.

12 days, PEth can be detected in blood for 3–4 weeks after alcohol

Data were collected from individual patient electronic medical

ingestion.5–7 This contrasts with other blood and urine alcohol detec-

records, which included provider and transplant coordinator notes,

tion tests such as blood alcohol concentration, ethyl glucuronide, ethyl

Transplant Committee letters sent to patients, laboratory testing

sulfate, and carbohydrate-deficient transferrin, which can detect alco-

results, and imaging. Basic patient data included age, sex, race/ eth-

hol use only from several hours to 1 week after consumption.8 This

nicity (categorized as Black/African American, white, Asian Ameri-

feature of PEth has led to its wide utilization in various clinical set-

can/ Pacific Islander [AAPI]/Other, and Hispanic [of any race]), and

tings for the detection of alcohol use, including in the liver transplant

body mass index (BMI). Presence of comorbidities—including diabetes,

setting.

hypertension, dyslipidemia, myocardial infarction, stroke, chronic kid-

Only a few small studies have assessed the use of PEth in the con-

ney disease, and hepatocellular carcinoma—were recorded. Additional

text of patient evaluation for liver transplant; these have demonstrated

data collected included whether liver disease was due to cirrhosis or

the ability of PEth to accurately assess alcohol use in patients pre- and

alcoholic-related hepatitis; PEth and non-PEth (serum ethanol or ethyl

post-transplant.9–11

However, there is little data regarding the impact

glucuronide) alcohol test results; reported alcohol use; Child-Pugh and

of PEth testing on transplant decisions and outcomes. In this study, we

Model For End-Stage Liver Disease (MELD) scores at initiation of eval-

sought to determine whether rates of transplant evaluation termina-

uation; and dates of initiation/ termination of transplant evaluation,

tions and delistings among patients with alcohol-related liver disease

placement on a transplant waiting list (listing), removal from waiting

differed in the pre-PEth versus PEth eras.

list (delisting), receipt of transplant, and/or death. Positive PEth was
defined as > 10 ng/dl.12 Reasons for evaluation termination or delisting were documented as well, and included positive PEth/ non-PEth

2

METHODS

testing, reported alcohol use, non-alcohol substance use, prohibitive
medical status, psychosocial concerns, need for completion of relapse

The study was designed as a retrospective cohort of liver transplant

prevention, patient preference, stable disease, patient enrolled in hos-

patients at Henry Ford Health System (HFHS), a large tertiary health

pice, and insurance issues. Household income was estimated based on

system in metropolitan Detroit, MI, USA. All study protocols were

US Census block group median household income mapped to patients’

approved by the HFHS Institutional Review Board; given the observa-

home addresses.

tional and de-identified nature of the data, the requirement for signed

Patients were followed from initiation of transplant evaluation

informed consent was waived. The study included transplant evalua-

until termination of evaluation (without listing), delisting, receipt of

tions listed in the Organ Transplant Tracking Record that were initi-

transplant, or death. Placement on the transplant list was defined as an

ated between 1/1/2017 and 11/12/2019; evaluations initiated in the

acceptance letter from the Transplant Committee in the medical record

2018 calendar year were excluded, therefore creating an exclusively

and registration in the United Network of Organ Sharing registry. Eval-

pre-PEth era (2017) and PEth era (2019).

uation termination was determined to occur if a patient underwent

Patients were considered if they had any component of alcohol-

transplant evaluation initiation, was not listed for transplant, and

related liver disease (e.g., alcohol alone or alcohol in combination

received a letter notifying them of conclusion of their evaluation,

with hepatitis C infection) and initiated evaluation for liver trans-

excluding those who died during their evaluation. Delisting was

plant during the two eras; patients with all other etiologies were

determined to occur if a patient completed evaluation, was listed for

3 of 6

SELIM ET AL .

transplant, and received a letter notifying them of removal from the

evaluation was initiated in the pre-PEth era, seven of which (10%) were

transplant list, excluding those who received a transplant or died while

due to alcohol use, and 85 evaluation terminations of patients whose

listed.

evaluation was initiated in the PEth era, 17 of which (20%) were due

The outcome of interest was a composite outcome of evaluation ter-

to alcohol use. Seventy-one of the pre-PEth era patients were placed

mination due to alcohol use or delisting due to alcohol use. “Alcohol

on the transplant list, 11 of whom (16%) were delisted; three of these

use” as a reason for evaluation termination or delisting was determined

(27%) were for alcohol use, two of which were detected with testing.

by testing (blood or urine testing in 2017; PEth in 2019) or reported

Fifty-nine of the PEth era patients were listed for transplants; two (3%)

alcohol use. Patients who received a transplant were censored at the

were delisted, both (100%) due to alcohol use detected with testing. Of

date of receipt. Death was considered a competing risk.

the delistings/terminations, there were a total of five (7%) for positive
urine/serum alcohol tests in 2017 versus 16 (19%) for positive PEth
tests in 2019. Among the pre-PEth era patients, 30/157 (19%) died dur-

2.1

Statistical analysis

ing evaluation, 6/71 (8%) died while listed and 49 received transplants.
Among the PEth era patients, 50/210 died during evaluation, 1/59 died

Patients were followed from initiation of transplant evaluation until

while listed, and 38 received transplants.

receipt of transplant, death, termination of evaluation, delisting, or

After IPW-weighting, patient characteristics were balanced

March 9, 2020, whichever was earliest. Inverse Probability Weight-

between the two eras (standard difference < .2). Figure 1 illus-

ing (IPW) was used to adjust for differences in the following baseline

trates the cumulative incidence curves of the composite outcome

patient characteristics between the samples of patients evaluated in

(terminations/ delistings due to alcohol use) stratified by PEth era.

the pre-PEth and PEth eras: variables included: year transplant evalu-

The final IPW-adjusted Fine-Gray model retained two significant

ation was initiated; sex; type of insurance; median household income;

variables (P < .05): PEth era and BMI category (Table 3). Patients

employment status; and marital status. Comparisons between pre-

that initiated transplant evaluation during the PEth era (2019) were

PEth and PEth eras were carried out using Chi-square tests for cat-

almost three times more likely to experience an alcohol-related

egorical variables and t-tests for continuous variables. The effect of

termination/delisting than those who initiated evaluation during the

era (pre-PEth vs. PEth) on risk of the composite outcome (evaluation

pre-PEth era (Fine-Gray subdistribution Hazard Ratio (sHR) = 2.86;

termination / delisting due to alcohol use) was tested using competing

95% Confidence Interval (CI) 1.67–4.97). In addition, patients with

risk analysis (Fine-Gray subdistribution hazard ratio method), adjusted

BMI 25–30 were less likely to experience evaluation termination or

for IPW weights and with death considered as a competing risk. Cen-

delisting due to alcohol use than those with BMI 18.5 < 25 (sHR = .40;

soring occurred if the patient received a transplant, their evaluation

95%CI .18–.90).

was terminated, or they were delisted for reasons other than alco-

We also performed a sensitivity analysis that used evaluation termi-

hol use. In addition to year of evaluation initiation (PEth era) variables

nations due to alcohol use (without delistings) as the outcome of inter-

used in the model included: race/ ethnicity, sex, BMI category (< 18.5,

est. Results were consistent with that of the main analysis (Supplemen-

18.5 < 25, 25 < 30, and ≥30); Child-Pugh score; MELD score; type of

tal table 1).

insurance; median household income; employment status; and marital
status. Stepwise backward elimination was used to determine the final
model; variables that yielded P-values < .05 were retained in the final

4

DISCUSSION

model.
The present study assessed the clinical impact of PEth testing on the
liver transplant process as it relates to rates of evaluation termina-

3

RESULTS

tion and delisting due to alcohol use. After using IPW to adjust for
baseline differences, we found that PEth era and BMI were asso-

Patient characteristics are shown in Table 1. A total of 375 patients

ciated with risk of termination/ delisting due to alcohol use using

had alcohol-related indications for liver transplant in the years of inter-

survival analyses that included death as a competing risk. In 2019,

est (157 in 2017 [pre-PEth] and 210 in 2019 [PEth]); eight patients

patients who initiated transplant evaluations were at almost three

were excluded due to lack of follow-up data after evaluation initiation.

times higher risk of transplant evaluation terminations/ delistings

There were 357 patients with alcohol-related cirrhosis, 29 patients

due to alcohol use compared to those who initiated evaluations

with alcohol-related hepatitis, and one patient with alcohol-related

in 2017, before the adoption of routine PEth testing of transplant

hepatitis superimposed upon alcohol-related cirrhosis. The majority of

candidates.

patients in both eras were white (90% and 84% in 2017 and 2019,

In general, the results of our multivariable analysis reflect factors

respectively) and male (67% vs. 68%). Mean MELD-Na scores were sig-

known to be related to likelihood of achieving a transplant. Although

nificantly higher in the PEth era (23.9 ±10.0 vs. 20.3 ±7.7; P < .001) as

it is not clear why patients with BMI 25 < 30 were less likely than

were the number of patients classified as Child-Pugh Class C (58% vs.

those with BMI 18.5 < 25 to be terminated/ delisted, it is possible that

49%).

patients with lower BMI may be experiencing inappetence, weight

Table 2 presents the outcomes of the included patients during

loss, and frailty and in overall poorer health.13,14 Interestingly, data

follow-up. There were 72 evaluation terminations of patients whose

has shown than beyond a BMI of 30, the risk of alcohol-related liver
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Univariate comparison of patient characteristics for the pre-PEth and PEth testing eras

Variable

Response

2017
(N = 157)

2019
(N = 210)

Race

Black/ African American

13 (8%)

19 (9%)

Hispanic (any race)

3 (2%)

9 (4%)

White

141 (90%)

177 (84%)

Sex

Median household income

Employment status

Insurance status

Marital status

BMI category

AAPI/ Other

0 (0%)

5 (2%)

Male

105 (67%)

142 (68%)

Female

52 (33%)

68 (32%)

<40k

40 (25%)

131 (63%)

40–60k

58 (37%)

35 (17%)

60–80k

41 (26%)

29 (14%)

80–100k

9 (6%)

11 (5%)

>100k

9 (6%)

3 (1%)

Employed

41 (26%)

54 (26%)

Not employed

107 (68%)

141 (67%)

Unknown

9 (6%)

14 (7%)

Medicare/ Medicaid

78 (50%)

125 (60%)

Private

76 (48%)

83 (39%)

Other / None

3 (2%)

2 (1%)

Married

80 (51%)

95 (46%)

Single/ Widowed/ Divorced

60 (38%)

83 (40%)

Significant other

16 (10%)

28 (14%)

<18.5

5 (3%)

6 (3%)

18.5- < 25

45 (29%)

60 (29%)

25-30

53 (34%)

70 (33%)

30 or higher

54 (34%)

73 (35%)

Test statistic*
value
5.72

.014

P-value
.129

.881

53.05

<.001

.14

.931

7.21

.027

1.38

.502

.039

.998

MELD

Mean ±SD

16.0 ± 8.1

20.8 ± 11.1

-4.85

<.001

MELD-Na

Mean ±SD

20.3 ± 7.7

23.9 ± 10.0

-3.92

<.001

Child-Pugh

Class A

4 (3%)

5 (3%)

2.90

.257

Class B

73 (49%)

77 (40%)

Class C

73 (49%)

111 (58%)

*Test statistic: T-statistic for continuous variables; Chi-square for categorical variables.
Abbreviations: BMI, body mass index; MELD, Model for End-Stage Liver Disease; MELD-Na, Model for End-Stage Liver Disease with sodium levels; SD, standard deviation.

disease actually increases likely due to the synergistic effect of obesity

transplant. Several studies have demonstrated the increased sensi-

and heavy alcohol use.15

tivity and specificity of PEth as compared to non-PEth alcohol tests

There is limited data addressing delisting due to laboratory testing

such as ethyl glucuronide and ethyl sulphate, in both the transplant

to detect alcohol use. In a 2010 article, Carbonneau et al.16 reported

and non-transplant settings.6,9–11 Additionally, the longer half-life of

a pre-transplant delisting rate of 17% due to alcohol use as detected

PEth has allowed for its detection up to a month following alcohol

by random blood alcohol levels. This was a significant increase from

use, unlike other alcohol tests which are typically detected no longer

a 5% delisting rate prior to the implementation of blood alcohol test-

than a week after alcohol use. Finally, its quantitative property allows

ing. Notably, although the delisting rate in that study was higher

the differentiation of light, moderate, and heavy alcohol use, which

than expected despite an extensive psychosocial evaluation, partici-

may be helpful for diagnostic purposes when attempting to deter-

pation in rehabilitation program, and regular office visits, it was felt

mine the etiology of liver disease (e.g., when attempting to distin-

to be in range with prior estimates of post-transplant relapse. This

guish between hepatitis due to heavy alcohol use versus decompen-

further emphasizes the need for regular, accurate testing for alco-

sated liver disease of alternate etiology with light background alcohol

hol use given the prevalence of relapse both prior to and following

use).
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TA B L E 2

Patients with alcohol-related indications for transplant in the pre-PEth (2017) and post-PEth (2019) eras
2017

2019

157

210

72 (46% of evaluations)

85 (40% of evaluations)

Terminated due to any alcohol use

7 (10% of terminations)

17 (20% of terminations)

Terminated due to alcohol use identified by testing

5 (71% of alcohol terminations)

16 (94% of alcohol terminations)

Evaluated
Evaluation terminated for any reason

Died during evaluation period
Placed on transplant list
Delisted for any reason

30

50

71

59

11 (16% of listed patients)

2 (3% of listed patients)

Delisted due to alcohol use

3 (27% of delisted patients)

2 (100% of delisted patients)

Delisted due to alcohol use identified by testing

2 (18% of delisted patients)

2 (100% of delisted patients)

6

1

49

38

Died before receiving transplant
Received transplant

F I G U R E 1 Cumulative incidence curves of the composite outcome of alcohol-related liver transplant evaluation terminations/ delistings due
to alcohol use, stratified by PEth era

TA B L E 3

Multivariable comparisons for composite outcome of alcohol-related evaluation terminations and delistings (as detected by testing)

Comparison

Adjusted Hazard
ratio (Confidence
limits)

Pairwise
comparison
P-value

Variable
P-value

versus

2017 (pre-PEth)

2.86 (1.67, 4.97)

<.001

<.001

versus

18.5 < 25

*

*

<.001

25–30

.37 (.17, .82)

.014

≥30

1.11 (.62, 1.99)

.736

Year

2019 (PEth)

BMI

<18.5

Patients were censored at transplant receipt. Death was considered as a competing risk only for patients placed on the transplant waiting list.
*Sample size too small for valid comparisons.
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One limitation of our study is that we were unable to formally evaluate the effect of changing practices concerning abstinence for patients
with alcohol-related indications for transplant. In recent years, many
transplant centers have moved away from absolute guidelines for alcohol abstinence prior to consideration of candidates to a “case-by-case”
basis, wherein select patients with alcohol-related hepatitis may be
considered for transplantation. At the time of our analysis, our institution maintained a “zero tolerance” policy for detected alcohol use
during the evaluation period and while wait-listed. We recognize that
many health systems are moving towards providing more support and
working with patients to meet program requirements for abstinence
from alcohol. However, we do not believe this limits the generalizability
of our main findings, since the ability to accurately detect alcohol use
during the evaluation/ listing period can identify patients who could
benefit from additional support in settings where patients with ongoing or relapsing alcohol use disorder may still be considered candidates
for transplant. Another limitation of our analysis is that—due to the
impact of the coronavirus pandemic—transplant operations within our
health system effectively came to a halt for several months in 2020. As
a result, we are unable to expand our study time frame to include more
years of follow-up, which would allow us to identify a larger patient
sample and perhaps include more variables in our analysis.
In conclusion, we found that a larger proportion of patients with
alcohol-related liver disease had transplant evaluations terminated or
were removed from waitlists due to alcohol use in 2019, after PEth
testing was implemented, compared to 2017. The other significant factors associated with evaluation termination/ delisting included BMI;
this is consistent with previous research and likely reflects overall
health status. Larger studies encompassing a longer time frame are
needed to clarify the impact of PEth testing on selection of candidates
for liver transplant, and whether its use results in more successful longterm outcomes.
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